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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Vascular Endothelial Growth Factor B (VEGF-B) är ett tillväxtprotein som styr mängden fett som 
transporteras genom blodkärlsväggen till celler, till exempel muskelceller. Genom att genmanipulera 
möss kan mängden VEGF-B minskas, vilket reducerar den mängd fett som transporteras igenom 
blodkärlsväggen och in i cellen.  
I delarbete I, undersöker vi hur VEGF-B regleras. Vi kan visa, både genom analyser i celler och i 
möss, att mängden VEGF-B styrs av ett protein känt som peroxisome proliferator-activated receptor γ 
coactivator 1α (PGC-1α). PGC-1α reglerar också antalet mitokondrier som finns i cellen. I 
mitokondrierna används de fetter som cellen tar upp för att utvinna energi. Eftersom PGC-1α också 
reglerar mängden VEGF-B, koordineras antalet mitokondrier med mängden fett som transporteras in i 
cellen, och därmed undviks sjuklig fettansamling.   
Patienter med Typ 2 Diabetes (T2D) har mycket högre mängder fett i centrala organ såsom hjärta, 
muskler och lever, jämfört med friska individer. I delarbete II ville vi undersöka om det felplacerade 
fettet kunde vara orsaken till att man utvecklar T2D. Vi kan i flera olika experimentella djurmodeller 
av T2D visa att om vi minskar mängden VEGF-B, genetiskt eller genom att använda en 
läkemedelskandidat, så reduceras även mängden fett i de centrala organen. Detta leder till att de 
djurmodeller som har mindre VEGF-B har en förbättrad sjukdomsutveckling. Därför skulle en 
läkemedelskandidat mot VEGF-B kunna erbjuda en lovande behandling för patienter med T2D. 
Diabetes är kopplat till ett flertal följdsjukdomar och diabetisk njursjukdom, även kallat diabetisk 
nefropati (DN), är en av dessa. I patienter med DN, har man kunnat observera höga mängder fett i 
njurarna. Vi ville därför i delarbete III studera om man genom att minska mängden fett i njurarna, 
genom att reducera mängden VEGF-B, kunde hindra eller förbättra sjukdomsutvecklingen. I flera 
musmodeller av DN kan vi visa att fett ansamlas i njurarna. Om man minskar mängden VEGF-B är 
fettansamlingen i njurarna kraftigt reducerat och dessa möss har även en mildare sjukdomsutveckling 
samt en bättre njurfunktion. Vidare visar vi även att patienter med DN har högre mängder VEGF-B i 
njurarna än friska individer. Att reducera mängden fett i njurarna, via VEGF-B antagonism, skulle 
därför kunna vara en möjlig behandling mot DN.  
Slutligen, i delarbete IV, har vi optimerat en metod som gör att man kan mäta mängden fett som finns 
i vävnaden. Denna metod har möjliggjort en noggrann kvantifiering av hur mycket fett som finns 
inlagrat, och har därför varit ovärderlig för samtliga delarbeten som diskuterats ovan.   
I denna avhandling föreslår vi sammanfattningsvis att en ökad inlagring av fett i centrala organ som 
muskel, hjärta och njure kan leda till T2D och DN. Genom att minska mängden VEGF-B, och 
därigenom fettansamlingen, kan vi bromsa utvecklingen av båda sjukdomarna. Därför anser vi att 
reduktion av mängden fett via minskad VEGF-B signallering, skulle kunna vara en ny lovande 
behandlingsmetod för patienter med T2D och DN.  
  
ABSTRACT 
Vascular Endothelial Growth Factor B (VEGF-B) was previously shown to control lipid 
uptake from the bloodstream via the endothelium into tissue cells, and when ablating Vegfb, 
intra-tissue lipid accumulation was reduced. However, very little is known regarding the 
metabolic role of VEGF-B in physiologic, or pathophysiologic conditions. 
In paper I, we characterized the upstream regulatory mechanism controlling VEGF-B 
expression. We showed in vitro and in vivo that peroxisome proliferator-activated receptor γ 
coactivator 1α (PGC-1α), a major regulator of mitochondrial biogenesis, controls the 
expression of VEGF-B. The tight regulation of VEGF-B via PGC-1α enables the 
coordination of lipid uptake with mitochondrial biogenesis and β-oxidation, and hence the 
prevention of lipotoxicity.  
Lipotoxicity and insulin resistance are suggested as key pathologies in type 2 diabetes (T2D). 
In paper II we analysed the effects of reduced VEGF-B signalling on lipotoxicty and disease 
progression in different rodent models of T2D. VEGF-B signalling was reduced by either 
genetic, or pharmaceutical means, and this reduced lipotoxicity, increased glucose uptake into 
peripheral tissues, improved dyslipidaemia and enhanced sensitivity to insulin, in rodent 
models of T2D. Therefore, targeting VEGF-B signalling is a promising therapeutic method 
for the treatment of T2D.  
Lipotoxicity has also lately been attributed a larger role in the pathogenesis of diabetic 
nephropathy (DN), a comorbidity of both type 1 diabetes (T1D) and T2D. Therefore, in 
paper III, we investigated the effects of reducing VEGF-B signalling in mouse models of 
DN. We showed that renal lipotoxicity was an important element of DN in these models, and 
by reducing VEGF-B signalling renal lipotoxicity was ameliorated. Also, renal function, 
morphology and the filtration capacity were enhanced. Furthermore, VEGF-B signalling was 
present and activated in patients with DN in comparison to healthy individuals. Thus, 
targeting VEGF-B signalling represents a novel therapeutic approach for DN. 
Finally, in paper IV, a protocol for detecting and imaging of intra-tissue neutral lipids is 
presented. This protocol enables the exact quantification of neutral lipids and was crucial for 
all papers discussed above.  
To conclude, our data show that lipotoxicity is a major driving force for the development and 
progression of T2D and DN. Hence, VEGF-B could be a novel target for the treatment of 
both T2D and DN.  
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1 INTRODUCTION 
Diabetes mellitus is a disease characterized by elevated blood sugar levels, referred to as 
hyperglycaemia. There are two major types of diabetes, type 1 and type 2 diabetes (T1D and 
T2D). Today, 387 million individuals are estimated to live with diabetes, although the 
prevalence is expected to increase with an additional 205 million diabetic individuals by 
20351. Diabetes is no longer a Western disease as, 77% of diabetic individuals today live in 
low- or middle-income countries1. Both types of diabetes increase the risk of long-term 
complications such as, cardiovascular disease, stroke, diabetic nephropathy (DN), diabetic 
retinopathy, diabetic foot ulcers, cancer and cognitive defects. Therefore, to find new 
therapeutic targets to treat these complications is of vital importance. In this thesis, we show 
that vascular endothelial growth factor B (VEGF-B) could be a target for the treatment of 
diabetes and DN. By reducing the signalling of VEGF-B, ectopic uptake of lipids into tissues 
was decreased. We also elucidate the regulation of VEGF-B expression via peroxisome 
proliferator-activated receptor γ coactivator 1α (Ppargc1a / PGC-1α). This introductory part 
aims to give a general overview of T2D, T1D and DN and the underlying mechanisms of 
these diseases. Also, a brief summary of the current research regarding VEGF-B and PGC-1α 
will be presented.  
1.1 DIABETES 
1.1.1 Type 2 Diabetes 
Ninety per cent of all subjects with diabetes suffer from the insulin-independent T2D. Major 
risk factors of the disease include genetic predisposition, obesity, high caloric diets, systemic 
hyperlipidaemia and physical inactivity. T2D is characterized by a state called insulin 
resistance, during which the cells of the body are not sensitive to insulin. Insulin signalling 
has numerous actions, all promoting the storage of dietary nutrients (Fig. 1a). In the insulin 
sensitive state, dietary glucose promotes insulin secretion from the pancreatic β-cells. In 
skeletal muscle, insulin increases glucose uptake via binding to the insulin receptor, which 
subsequently translocates glucose transporter 4 (GLUT4) to the plasma membrane (Fig. 2). In 
the liver, insulin promotes glycogen synthesis and de novo lipogenesis while gluconeogenesis 
is inhibited. In the adipose tissue (AT), insulin supresses lipolysis and promotes lipogenesis 
(Fig. 1a) 2. 
In the insulin resistant state, many key actions of insulin are reversed with large consequences 
for whole body metabolic homeostasis (Fig. 1b). Insulin resistance reduces muscular glucose 
uptake and instead glucose accumulates in the bloodstream3. Hyperglycaemia is counteracted 
by an increase in the secretion of insulin from the pancreatic β-cells 4,5 and consequently islet 
hyperplasia develops 4,6. In parallel, islet hyperplasia causes an increase in the production of 
glucagon from the pancreatic α-cells. In the liver, this together with hepatic insulin resistance, 
results in elevated glucose production (gluconeogenesis) contributing to hyperglycaemia6. If 
this state is left untreated, β-cell exhaustion and apoptosis will develop and ultimately insulin 
production will be lost. Insulin resistance in the adipocytes results in lack of insulin-mediated 
 2 
inhibition of lipolysis, thus fatty acids (FAs) are released and accumulate in peripheral 
tissues7,8. Atypical lipid accumulation is also promoted by increased de novo lipogenesis in 
the liver and by upregulation of muscular lipid uptake9,10.  
 
Fig 1. Schematic overview of key events in insulin sensitive and insulin resistant states  
a): In the insulin sensitive fed state, dietary glucose promotes insulin secretion that 1. increases muscular 
glucose uptake, 2. promotes glycogen synthesis and inhibits gluconeogenesis, 3. increases hepatic de novo 
lipogenesis, 4. supresses lipolysis and promotes lipogenesis in AT.  b) In the insulin resistant fed state 1. 
muscular glucose uptake is decreased  2.elevating both insulin and glucagon secretion. 3. Hepatic 
gluconeogenesis is elevated and glycogen synthesis is reduced and 4. lipolysis is increased in AT. GLUT4, 
glucose transporter 4, TG, triglycerides, AT; adipose tissue. Derived from 11-14 
Hence, as diabetes proceeds, glucose, lipid species, glucagon and insulin accumulate in the 
bloodstream. However, the exact order in which these events occur and their interconnected 
importance is still debated. 
 
Fig 2. Schematic overview of insulin signalling and glucose transport  
Insulin binds to the insulin receptor, leading to phosphorylation of IRS, that in turn recruits PI3K. The P110 
subunit is activated, producing the lipid second messenger PIP3 from PIP2. PIP3 phosphorylates PH-domain 
containing proteins, PDK1, PKCξ-λ and PKB. PKB phosphorylation inhibits AS160, which relieves its inhibitory 
effect on GLUT4, triggering translocation to the plasma membrane. PKB phosphorylation also activates 
pathways involved in protein and glycogen synthesis.  
MAPK; Mitogen-activated protein kinases, IRS; Insulin Receptor Substrate, PI3K; Phosphatidylinositol-4,5-
bisphosphate 3-kinase PIP3; Phosphatidylinositol (3,4,5)-trisphosphate, PIP2; Phosphatidylinositol 4,5-
bisphosphate, PDK1; 3-phosphoinositide dependent protein kinase-1, PKC; Protein kinase C, PKB; Protein 
kinase B, AS160/ TBC1D4; TBC1 domain family, member 4. 
Insulin
Glucose transport
Glycogen synthesis
Glycogen synthesis
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Traditionally, it has been assumed that insulin resistance primarily, and only, develops in 
cells with established functions in glucose handling, such as myocytes, adipocytes and 
hepatocytes4. However, data has shown that insulin resistance also develops in other cell 
types such as podocytes15 and endothelial cells (ECs)7. Insulin resistance in ECs even 
precedes that in myocytes16,17,7 which was supported by a study, where IRS2 was ablated 
specifically in ECs in mice. These mice displayed reduced muscular insulin delivery, 
capillary recruitment and insulin-induced endothelial nitric oxide synthase (eNOS) 
phosphorylation18.  
1.1.1.1 Mechanisms of insulin resistance 
Several different mechanisms underlying insulin resistance in T2D have been suggested, the 
two best studied are hyperglycaemia (glucotoxicity) and lipotoxicity.  
1.1.1.1.1 Glucotoxicity 
Hyperglycaemia impairs both the action of and the secretion of insulin, and has been regarded 
as the major pathology causing T2D. Today, most of the T2D drugs on the market act to 
reduce glucose levels by different molecular mechanisms. A vast amount of studies have 
been published regarding how the insulin signalling pathway is affected by hyperglycaemia, 
often focusing on how insulin release from the pancreatic islets is altered.  
Chronic elevation of plasma glucose levels increased the generation of reactive oxygen 
species (ROS) that impaired both insulin secretion and action19. In line with this, levels of 
markers for oxidative stress were increased in pancreatic islets from T2D subjects compared 
to islets from non-diabetic subjects20. Moreover, the intracellular concentration of these 
oxidative stress markers was inversely correlated to glucose-stimulated insulin release from 
β-cells20,21. Glucotoxicity could also induce the activation of the unfolded protein response 
(UPR), also termed endoplasmic reticulum (ER) stress in pancreatic β-cells and in 
hepatocytes22,23. ER stress have been shown to contribute to the development of hepatic 
insulin resistance via activation of enzymes involved in gluconeogenesis, lipogenesis and 
kinases involved in the UPR pathway10. Furthermore, hyperglycaemia induced ER-stress in 
islets from T2D subjects, but not in islets from non-diabetic subjects22. Finally, chronic 
hyperglycaemia affected insulin secretion and insulin resistance by increasing flux through 
the hexose biosynthetic pathway24 thus inactivating Akt2 mediated GLUT4 translocation25,26. 
However, a direct causal relationship between hexose biosynthetic pathway and insulin 
resistance has not yet been established27.  
Large cohort studies have been conducted to explore whether intensive management of blood 
glucose levels using anti-diabetic agents, could reduce the risk for diabetes-related deaths and 
comorbidities. The ACCORD consortium study included 10,000 patients with T2D with an 
elevated risk for cardiovascular disease, and patients were randomly assigned to intensive 
therapy (HbA1c ≤6.0%), or standard therapy (HbA1c 7.0–7.9%). Surprisingly in the intensive 
group in which blood glucose levels were normalized, no significant difference in the primary 
end points (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular 
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causes) were detected. All-cause mortality was even 22% higher, in the intensive therapy 
group28. In a more recent ACCORD trial with a similar setup, an increased risk of 
cardiovascular events and mortality was found in younger participants in the intensive 
therapy group, whereas no effect was found in older participants29.  
Taken together, even though the T2D agents available today are efficient in lowering blood 
glucose levels, even to normoglycaemic levels, they do not prevent diabetes-related 
complications. This implies that other mechanisms, perhaps more significant than 
glucotoxicity, may contribute to diabetes and its complications. 
1.1.1.1.2 Lipotoxicity 
Considering that T2D typically develops in association with weight gain, prolonged physical 
inactivity, and/or systemic hyperlipidaemia, it is seemingly intuitive that insulin resistance 
might be driven by an excess of lipids. Indeed, research has provided a strong causative 
relationship between insulin resistance, organ dysfunction and atypical storage of neutral 
lipids in tissues such as liver, heart, pancreas, and skeletal muscle6,30-32. Lipids stored outside 
the adipose tissue are the most dangerous ones33,34 and individuals with more abdominal 
obesity are more susceptible to metabolic syndrome35 due to lipid overflow to other organs. 
High intramyocellular lipid (IMCL) content in both humans and rodents were associated with 
insulin resistance36,37 and was a stronger predictor of insulin resistance than circulating FAs38. 
Infusing lipids into cardiac and skeletal muscle in healthy subjects induced insulin 
resistance39,40. In line with this, weight loss decreased IMCL content together with an 
improved insulin sensitivity41, and reversely, lipid infusion in combination with a high-fat 
diet (HFD) increased IMCL content and impaired insulin sensitivity in healthy subjects42. 
Why do lipids accumulate in the peripheral tissues in diabetic patients? A common 
observation from diabetic rodent models is that atypical lipid accumulation and insulin 
resistance are linked to the absence of functional adipocytes34,43. Restriction of the adipocyte 
expansion capacity in db/db mice prevented obesity but instead increased cardiac and liver 
lipid accumulation rendering the animals diabetic34. In contrast, when overexpressing 
adiponectin in diabetic mice, thus increasing adipocyte number, the mice became overtly 
obese but still maintained normoglycaemia43. Also, lipodystrophy patients characterized by 
progressive loss of AT, generally display metabolic disorders such as insulin resistance, T2D 
and hyperlipidaemia44. Studies have indicated that subcutaneous AT is the largest and least 
metabolically harmful storage site of excess fat45. Atypical fat accumulation may therefore be 
due to a limited ability of this tissue to recruit new adipose cells and thus retain a bulk of the 
lipids that have been ingested46.  
Several different lipid species have been shown to affect insulin signalling and/or insulin 
mediated glucose uptake in multiple organs (Fig. 2 and 3)32. Diacylglycerols from lipid 
droplets (LDs) activated PKCθ that altered the phosphorylation pattern of the IRS-1, leading 
to decreased insulin receptor signalling47. Ceramides, synthesised from esterification of FAs 
and sphingosines, can inactivate Akt2, consequently inhibiting the translocation of GLUT4 
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vesicles to the cell surface47-49. Impaired Akt2 activity also decreased insulin-mediated 
glycogen synthesis, which further contributed to the development of hyperglycaemia50. 
Obesity caused an inflammation in AT that may develop into a low-grade chronic 
inflammation in the whole body51. Increased expression of pro-inflammatory cytokines such 
as tumour necrosis factor alpha (TNFα) have been detected in the AT in rodents and diabetic 
subjects with insulin resistance52,53. Increased TNFα signalling in AT promoted lipolysis via 
decreased expression of proteins stabilizing LD54,55 causing lipid overload in peripheral 
tissues. Furthermore, elevated circulating levels of TNFα impaired insulin signalling via 
inactivation of IRS-156. ER stress activated enzymes involved in e.g. lipogenesis10 and altered 
cellular lipid balance in muscle and AT via accumulation of lipid intermediates, thus 
interfering with insulin signalling23. Finally, muscular mitochondrial content was lower in 
obese and T2D subjects57. Decreased β-oxidation would increase lipid accumulation and fuel 
the viscous cycle of lipotoxicty and impaired insulin signalling, but whether or not 
mitochondria have a causal role in insulin resistance is still debated.  
 
Taken together, several lipid-mediated mechanisms in various organs have been shown to 
contribute to the pathogenesis of insulin resistance and T2D (Fig 3).  
1.1.2 Type 1 Diabetes  
T1D stems from a deficiency of insulin production caused by a destruction of β cells as a 
result of an autoimmune attack (advanced type 1 diabetes) and usually manifests before 10 
years of age. However, there is a notable heterogeneity of the disease and several other 
variants of insulin deficiency occur in patients with e.g. pancreatitis and some monogenic 
forms of diabetes58. Traditionally, T1D and T2D have been considered as two different 
diseases, however today the borderline between these two is not as clear. Experimental 
evidences from both human subjects and experimental animal models suggest, that insulin 
resistance may also be present in T1D59. For unclear reasons, there is a 4% annual increase in 
the prevalence of T1D in European children60,61 but similar trends are observed 
Inflammation
a) b)
Insulin
Glucose
Lipids
GLUT4
GLUT4
Insulin receptor
c)
d)
e)
f)
Fig 3. Overview of the mechanisms behind lipid-
induced insulin resistance 
Lipid-induced insulin resistance can occur via; a) 
Inhibition of the insulin receptor substrate and 
intracellular insulin signalling b) Trapping vesicle 
fusion proteins preventing GLUT4 translocation c) 
Mitochondrial dysfunction as well as d) inflammatory 
responses and e) lipid spill-over from adipose tissue. 
f) ER-stress activates lipogenesis, contributing to 
high IMCL levels.  
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worldwide62,63. Children with both T1D and T2D, are increasingly more often observed in the 
clinic64 as the rise in childhood obesity has resulted in elevated prevalence of T2D also in 
children65,66.  
Despite adequate or even higher insulin availability, supplied by insulin therapy, lower 
whole-body insulin sensitivity was detected in T1D patients. Other hallmarks of T2D have 
been found in T1D patients such as reduced insulin-stimulated glucose clearance59 and 
abnormal mitochondrial function67. At the molecular level, lower expression levels of the 
insulin receptor and GLUT4 were found in lean68 and obese T1D patients69. Thus, insulin 
resistance does not only occur in T2D but also in T1D subjects and the overall metabolic 
consequences seem to be similar, although more studies on this topic are required.  
May lipotoxicity be the underlying mechanism of insulin resistance in T1D subjects as well, 
even though obesity is not a predictor, or a trait of the disease? Abnormal lipid accumulation 
in the liver70 heart and muscle59 has been observed in T1D subjects. Also, high IMCL content 
was associated with the development of insulin resistance in these patients59. Furthermore, 
T1D patients displayed adverse changes in HDL/chylomicron metabolism in response to 
multiple high-fat meals71. Additionally, insulin resistance was detected in AT in T1D 
patients69 indicating an impaired insulin-mediated suppression of lipolysis72. T1D mice 
lacking perilipin 5 (Plin5-KO), an essential component that protects LDs from attack by 
lipases, did not exhibit excessive ROS generation or heart malfunction in contrast to T1D 
control mice. This was contributed to lower cardiac levels of diacylglycerol and ceramides 
detected in Plin5-KO compared to wild-type (WT) mice73. Hence, lipids may accumulate in 
liver and muscle also in T1D patients. 
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1.2 DIABETIC NEPHROPATHY 
Currently, DN is the leading cause of chronic kidney disease and one of the major mechanisms 
underlying diabetes-related deaths. This section will cover the structure and function of the 
kidney, followed by a discussion of the pathological alterations occurring in DN. 
1.2.1 Kidney anatomy and function 
The kidney filters the blood by excreting waste products to the urine and allowing molecules 
that are to be re-used to re-enter into the bloodstream. Proper secretion and reabsorption 
ensures metabolic homeostasis and normal blood pressure. Blood that is to be filtered enters 
the kidney via the renal artery, and is then directed to smaller arterioles in the cortex, ultimately 
entering the nephrons, which are the filtration units of the kidney. The nephrons are composed 
of the renal corpuscle where the initial filtering occurs and the renal tubule specialized for 
reabsorptions and secretion. After passing through the renal tubule, the filtrated urine continues 
to the collecting duct system consisting of a series of tubules and ducts that finally connect the 
nephrons to the ureter (Fig 4)74,75. 
 
Fig 4. Schematic overview of the kidney and the morphology of the nephron 
The outer and inner part of the kidney are called the cortex and the medulla. Derived from 76  
1.2.1.1 Renal corpuscle 
Renal corpuscles are situated in the beginning of the nephron and act as the initial filtering 
component. The renal corpuscle consists of the glomerulus and the surrounding Bowmans 
capsule. Both the nephron and Bowmans capsule contain several different cell types, which 
all in synchrony maintain a proper filtration barrier (Fig 4 and 5)74,75. 
Blood enters the glomerular capillaries via the afferent arteriole where an initial filtration 
occurs. This capillary network is referred to as the glomerular filtration barrier (GFB). Blood 
that has been filtered exits the glomeruli via the efferent arteriole and after returning from the 
inner medulla returns to the renal vein and the general circulation. A hydrostatic pressure 
created by the afferent and efferent arteriole exists in the glomerular capillaries allowing the 
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ultrafiltration of metabolic waste products and other small molecules such as water, glucose, 
amino acids, urea and sodium. Larger molecules such as albumin, immunoglobulins and 
plasma transport proteins are largely retained in the blood. Molecules and waste products that 
have been filtered through the glomerular capillaries, depicted as the primary urine, end up in 
the space between the podocytes and the parietal epithelial cells that line the Bowmans 
capsule. Here is where the primary urine is collected before being led out to the renal 
tubule74,75. 
In detail, GFB is composed of ECs, glomerular basement membrane (GBM) and podocytes 
(Fig 5). Renal ECs are fenestrated and would thus allow for free passing of fluid, plasma 
solutes and proteins, but trap red blood cells77. However, electron microscope images have 
shown that negatively charged glycocalyx are bound to the luminal side of the endothelium, 
also covering the fenestrae78. Thus, macromolecules are retained in the blood by the ECs 
based both on charge and size79. The GBM consists of laminins, type IV collagen, nidogen 
and heparan sulfate proteoglycans, synthetized by ECs and podocytes80. GBM contributes to 
the filtration process based on size and charge but also constitutes the main structural support 
for the glomerular capillary wall81. Podocytes, that are specialized and differentiated cells, 
consist of a cell body, major processes and foot processes and have an essential role in 
maintaining the filtration barrier (Fig 5.). The podocyte foot processes interact with the 
neighbouring podocytes and are regulated by their actin cytoskeleton. The filtration slit 
constitutes the space between foot processes, and is bridged by the slit diaphragm82. The slit 
diaphragm is a structure composed of several different molecules that all have specific roles 
in maintaining the podocyte specific filtration barrier 82-84. Apart from size exclusion, the 
exact filtration capacity of the slits is still debated. 
Fig 5. Schematic overview of the renal corpuscle, renal capillaries and the glomerular filtration barrier  
CD2AP ;CD2-associated protein. Derived from 76 
1.2.1.2  Renal tubule 
The renal tubule (Fig. 4) is the latter part of the nephron and holds the primary urine that has 
been filtered through the glomerulus. The primary urine passes through the proximal 
convoluted tubule that constitutes of an epithelial cell layer connected by tight junctions. Here 
glucose and about 70% of the sodium and water are reabsorbed from the primary urine. Next 
in the loop of Henle, a U-shaped tubule, sodium and the remaining water are reabsorbed. 
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Finally, in the distal convoluted tubule, sodium is reabsorbed through coupled secretion of 
protons and potassium ATP-dependent ion channels74,75. 
1.2.2 Pathology of diabetic nephropathy 
DN is caused by impaired filtration capacity of the kidney, and as a consequence larger 
molecules, like proteins, will leak into the urine85. Both genetic and environmental factors 
contribute to the development of DN. The disease slowly progresses over several years, and 
during the later stages there is a subsequent decline in the glomerular filtration rate that may 
ultimately lead to end-stage renal disease (ESRD)86. With the global increase in the 
prevalence of diabetes, the number of renal replacement therapy patients is also rapidly 
rising87,88.  
The major histopathological characteristic of DN is the presence of glomerular lesions 
referred to as glomerusclerosis89. A clinical indication of an injury to the GFB is the presence 
of albuminuria85, however among the first histological signs of DN is thickening of the GBM 
and glomerular mesangial expansion (GME)89. GME leads to the development of 
glomerusclerosis, which may be focal, diffuse, segmental or global90. Also, an increase in the 
overall size of the glomerulus is detected, probably due to GME as well as a compensatory 
hyperfiltration89. Leakage in the glomeruli increases the pressure on the tubule to reabsorb 
solutes, which in turn activates the renin-angiotensin-aldosterone system (RAAS). RAAS 
activation increases both blood pressure91 and the hydrostatic pressure in the glomeruli that 
may cause thickening of both the afferent and efferent arteriole. This morphology is referred 
to as arteriolar hyalinosis. In advanced nephropathy, tubular atrophy and interstitial fibrosis 
are also observed92, which can be a compensatory mechanisms for hypertension and the 
increased volume of the glomerular filtrate. Injury to the proximal convoluted tubule is 
further enhanced by an increase in sodium reabsorption and oxidative stress, which further 
contributes to hypertension93.  
Several different animal models recapitulate relatively well the phenotypic characteristics of 
DN, most studies include the T2D model db/db and the T1D STZ-injected mouse models 
(Fig. 6). However, they do not recapitulate all the morphologies detected in DN patients and 
mentioned above, and often consist of complicated genetic mutations, or toxic agents. 
Therefore, much research is focused on finding novel animal models94. 
 
Fig 6. General glomerular morphology in health and disease 
Periodic acid–Schiff staining of glomeruli from normal or DN subjects, T2D db/db and STZ-treated T1D mouse 
models. The animal models recapitulate well the general morphology of DN with GME and thickening of 
Bowmans capsule basement membrane. However, the Kimmelstiel-Wilson Nodules are not detected in any 
animal models. STZ; Streptozotocin. Modified from 76,95,96 
normal subject DN subject STZ-treated 
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It is still debated in which cell type the primary injury of DN occurs. Even though the tubule 
is affected, most studies indicate that injury to GFB is the causative factor for disease 
development. Specifically, mutations in genes coding for slit diaphragm proteins such as 
nephrin, CD2AP and podocin (Fig. 5), cause nephropathies97-99 showing the importance of, at 
least, the slit diaphragm and podocytes in maintaining functional GFB. In line with this, 
podocyte number correlated inversely with albuminuria100 and reduced podocyte numbers 
were reported in both T1D101 and T2D102. Furthermore, podocyte detachment103 and 
apoptosis104 contributed to reduced GFB capacity in DN patients. Additionally, widening of 
podocyte foot processes has been observed in renal biopsies of diabetic patients with 
increased albumin excretion105,106.  
1.2.2.1  Mechanisms underlying DN 
The molecular mechanisms behind the abnormal glomerular alterations in DN are not 
understood. Homeostasis of the GFB depends on the integrity of podocytes, ECs and GBM 
and therefore, one could argue that any factor injuring, or changing the behaviour of any of 
these cell types may cause renal damage. The major causative factors for DN include 
hyperglycaemia and lipotoxicity84.  
Over the years hyperglycaemia has predominantly been suggested to contribute to the 
pathogenesis of DN. Hyperglycaemia triggered the synthesis of advanced glycation end-
products (AGEs) and induced oxidative stress107. Furthermore, hyperglycaemia promoted the 
synthesis of angiotensin II of the RAAS system91, that affects normal podocyte function and 
afferent arteriolar tone108,109. High levels of angiotensin II caused hypertension and induced 
cell damage, leading to proteinuria and initiating glomerulosclerosis110. Hyperglycaemia also 
activated transforming growth factor β (TGF-β), a key factor that drives the activation of 
fibroblasts, and thus renal fibrosis108. Also, activated TGF-β diminished the expression of 
nephrin on the slit diaphragm111.  
Today, interventions against DN focus largely on targeting hyperglycaemia, blood pressure 
and lifestyle changes. However, the prevalence of DN has increased in parallel with diabetes, 
despite higher usage of glucose-lowering agents112. Large cohort studies on T2D patients 
have been conducted to explore whether intensive management of blood glucose levels using 
anti-diabetic agents, could reduce the risk for DN and ESRD. Despite intensively controlled 
blood glucose levels, albuminuria was only slightly improved and serum creatinine levels 
were unaffected113,114. Furthermore, there was little or no effect on the incidence of ESRD 
and no change in death from renal disease despite intensive blood glucose management113,114.  
Lipotoxicity has therefore lately been considered as a major underlying factor of the 
pathogenesis of DN. Already the original article on glomerulosclerosis in subjects described 
lipid deposits in the glomeruli90, and these were later confirmed by electron microscopy. 
Also, a high correlation between glomerular filtration rate, inflammation and lipid 
metabolism genes was detected in subjects with DN115. Lipids were shown to accumulate 
specifically in the podocytes115 and podocytes treated with sera from patients with DN 
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displayed increased cholesterol levels, which were detrimental for podocyte cell function116. 
Higher intracellular lipid accumulation was found in tubule from patients with chronic kidney 
disease and mice with tubulointerstitial fibrosis in comparison to healthy controls117. 
Genetically manipulated mice with tubulointerstitial fibrosis could be protected from disease 
development if FA metabolism was restored117. Furthermore, oxidised LDL is associated 
with the progression of DN118and overexpression studies of the receptor for oxidised LDL 
and lipoproteins in mice, increased the expression of TGF-β, vascular endothelial growth 
factor A (VEGF-A) together with kidney failure119. VEGF-A is secreted by podocytes, and its 
expression has been shown to be either up- or down-regulated in diabetic subjects, depending 
on the duration and stage of the disease120,121. VEGF-A seems to maintain the integrity of the 
GFB as both podocyte-specific excess, or deficiency, cause glomerular damage122,123. 
Interestingly, podocytes can also develop insulin resistance. Podocytes express all 
components of the insulin-signalling cascade and glucose uptake in podocytes was increased 
after insulin stimulation, mainly through translocation of GLUT4124. It was found that insulin 
resistance correlated with the development of albuminuria in both T1D and T2D subjects125-
128. Additionally, impaired insulin sensitivity altered renal glucose cell metabolism and 
caused kidney damage independent of hyperglycaemia128 and GLUT4 expression was 
downregulated upon the development of albuminuria129. Mice carrying a podocyte-specific 
deletion of the insulin receptor gene developed a phenotype resembling DN without any 
effect on blood glucose levels15. There have been a few studies elucidating what mechanism 
causes insulin resistance in podocytes, and linking lipotoxicity as the causative factor. 
Palmitate could block insulin-stimulated glucose uptake in human podocytes in vitro, 
suggesting a lipid-mediated inhibitory effect on insulin sensitivity130. Indeed, increased 
ceramide production in podocytes caused reduced phosphorylation of the insulin receptor and 
impaired translocation of GLUT4 to the cell surface130. Furthermore, LDL131 and saturated 
FAs have also been shown to affect podocyte function an induce insulin resistance130. Taken 
together, lipotoxcicity and insulin resistance in podocytes could be important contributors to 
the disruption of the GFB.   
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1.3 ENDOTHELIAL LIPID UPTAKE  
Lipids are the most energy dense nutrients, and are vital for normal cell processes and 
function. Reliable systems for transport of lipids to all cells of the body are therefore 
imperative. Nutrients are delivered to tissue cells via blood vessels, characterized by a lining 
of ECs, the endothelium, covering the inner surface and thus adjacent to the blood that passes 
through. It has for long been acknowledged that the endothelium has a barrier function132. 
However, it has been overlooked that nutrients such as lipids, going from the bloodstream 
into the tissue cells, also have to pass the endothelium. The preferred sort of nutrient varies 
between tissue and cell type and may also change upon different physiological stimuli. 
Therefore, mechanisms controlling nutrient uptake should exist. Furthermore, it would also 
demand less energy for the organism to limit nutrient uptake already at the vascular wall.  
Research has shown that the endothelium can act as a barrier for FA uptake133-135. However, it 
was only recently that a detailed mechanism for how myocytes can regulate lipid uptake 
through the endothelium was discovered, via secreting VEGF-B136. 
1.3.1 Lipid transport and lipid transporters 
Organs with high metabolic activity such as heart, skeletal muscle and brown adipose tissue 
use lipids as their primary nutrient source. Most dietary lipids consist of long chain fatty 
acids (LCFAs, FAs with 12-20 carbons). FA are transported in the bloodstream either as 
TG rich lipoproteins during fed-states, or bound to albumin during fasting137. TGs are 
hydrolyzed at the site of peripheral tissues by lipoprotein lipase, which is anchored at the 
luminal side of the endothelium138. Research has focused on LCFA transport across the 
sarcolemma139,140 since lipids were suggested to simply diffuse through the endothelium. 
However, secreted VEGF-B from tissue cells has been shown to signal in a paracrine 
fashion to the endothelium to induce the expression of two fatty acid transport proteins, 
FATP3 and FATP4 (Fig. 8) and consequently promote regulated lipid uptake136. 
FATP3 and 4 belong to the evolutionary conserved FATP family constituted of six 
mammalian 70-80 kDa large multi-transmembrane spanning proteins (FATP1-6)141,142. 
Fatp4 is abundantly expressed, for example in myocytes, skin and in the endothelium141,143 
whereas Fatp3 is expressed specifically in the vasculature at least in muscular tissues136. 
Fatp4-/- mice are embryonically/neonatally lethal143 due to defects in FA absorption and/or 
to a disrupted epidermal barrier143. All FATPs have been shown to enhance cellular FA 
uptake in vitro136,144. However, the subcellular localization of the FATPs has been debated 
as well as if they simply drive cellular FA influx by intracellular acylation of FAs145  
1.3.2 VEGF-B signalling 
The VEGFs have a major role in controlling angiogenesis and lymphangiogenesis, both 
during embryogenesis and in the adult state146,147 as well as during pathophysiological 
conditions148. Mammalian members include VEGF-A, VEGF-B, VEGF-C, VEGF-D and 
placenta growth factor  (Plgf)148. VEGFs act by binding to the tyrosine kinase receptors: 
VEGF receptor (VEGFR) 1, VEGFR2, VEGFR3 and the co-receptor neurophilin (NRP)-1 
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in an overlapping pattern (Fig. 7). VEGF-B binds to VEGFR1 and NRP1. VEGF-B is 
synthetized as two isoforms by alternative splicing, VEGF-B167 and VEGF-B186149,150. In 
adults, VEGF-B167 is the prevalent isoform and binds to cell surface heparan sulphate 
proteoglycans151. On the contrary, VEGF-B186 is freely diffusible and requires proteolytic 
cleavage before binding to NRP1152. However, the exact signalling mechanism of VEGF-
B/NRP1/VEGFR1 is still far from understood. 
 
Fig 7. VEGF receptors, ligands and signalling   
The VEGF ligands bind to VEGFRs in a partially overlapping fashion. VEGF-B, PlGF and VEGF-A also 
bind to the co-receptor NRP1 (grey arrows). Dashed lines indicate that proteolytic cleavage is needed before 
receptor binding. From153 
1.3.2.1 VEGFR1 and NRP1, receptors of VEGF-B 
VEGFR1 is a member of the tyrosine kinase receptor superfamily with an approximately 
750-amino-acid-residue extracellular domain that binds VEGF-A, -B and PlGF154. The role 
of VEGFR1 during development has been extensively studied, during which VEGFR1 seems 
to primarily trap VEGF-A155, via its higher affinity for VEGF-A156 and thus hinder VEGF-
A/VEGFR2 signalling. Vegfr1-/- as Vegf+/- embryos, die prenatally155,157, whereas deletion of 
only the intracellular signalling domain of VEGFR1 (Vegfr1 TK-/- mice) resulted in healthy 
and fertile mice158. VEGFR-1 has the ability to bind tightly to its ligands but has a weak 
tyrosine kinase activity, generating signals weaker than VEGFR-2159. Therefore, it was 
suggested that VEGFR1 in the adult state does not have a signalling capacity per se but rather 
acts as solely a sink, trapping VEGF-A160. Even though the signalling capacity of VEGFR1 is 
not yet exactly understood, recent data has shown that upon stimulation with VEGF-A or 
PlGF, VEGFR-1 can initiate phosphorylation of distinct downstream proteins in 
monocytes147,161. Vegfr1 is expressed on ECs, monocytes and macrophages162,163 and has 
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been shown to be a positive regulator of monocyte and macrophage migration161,162 and to 
have a role in tumour progression164.  
NRP1 is a 130- to 140-kDa transmembrane glycoprotein165 and is expressed in ECs, neural 
progenitors, macrophages and myocytes166-168. NRP1 has been shown to contain a PDZ-
domain in its C-terminus, which enables the binding and signalling to downstream targets 169. 
NRP1 is important for normal nervous system development and required for blood vessel 
patterning and normal lymphatic valve formation170,171.  
1.3.2.2 The biological function of VEGF-B 
VEGF-B was for long assumed to have a similar function as its closest homologue, VEGF-
A. Therefore, several studies have focused on VEGF-B in areas related to the known 
functions of VEGF-A. However, in contrast to the other VEGFs, VEGF-B is not 
upregulated by hypoxia, poorly angiogenic and does not induce vascular permeability in 
animals or tissues172-174. Although Vegfb-/- animals are healthy and fertile and present a 
normal life span175, VEGF-B has been reported as a survival factor for different cell types 
by inhibiting apoptosis176,177. Vegfb-/- animals have minor cardiac abnormalities, such as 
smaller hearts and an increased PQ interval175,178. VEGF-B has been shown to induce 
arteriogenesis, both in rats with cardiac VEGF-B overexpression and in pigs with local 
adenoviral delivery of VEGF-B174,179. Increased VEGF-B levels have also been implicated 
in the development of different cancers180. In contrast, retarded tumour growth was detected 
when overexpressing VEGF-B in a mouse model for pancreatic cancer (RIP-Tag)181. 
Hence, the role of VEGF-B in angiogenesis, cell survival and tumour growth remains 
enigmatic. 
Vegfb is expressed in tissues with high metabolic activity with enriched mitochondrial 
content such as heart, skeletal muscle and brown fat136,151,152. Mice with cardiac VEGF-B 
overexpression, displayed increased accumulation of ceramides, hypertrophy, mitochondria 
lysis and premature death182. When overexpressing VEGF-B by adenoviral delivery in pig 
and rat heart two diverging metabolic states were detected. Overexpression of VEGF-B in 
pig myocardium caused an upregulation of the Fatps as well as tissue lipid accumulation183. 
In contrast, VEGF-B overexpression in rats downregulated genes involved in FA 
metabolism whereas glucose uptake was increased179. These opposite effects may stem 
from receptor saturation, as techniques such as adenoviral delivery or transgenic 
overproduction may produce unphysiological protein levels. 
Genetic deletion of Vegfb in mice decreased the expression of muscular Fatps and 
peripheral FA uptake, and instead the FAs were shunted to the AT136. The FA transport 
capacity was unique for VEGF-B as endothelial cells stimulated with, PlGF or VEGF-A, 
did not upregulate the expression of FATPs and FA transport. The FA uptake capacity was 
also dependent on both VEGFR1 and NRP1. Vegfr1 TK-/- and inducible EC-specific Nrp1-/- 
mice displayed reduced cardiac Fatp3 and Fatp4 expression and tissue lipid 
accumulation136. Positron emission tomography analysis of Vegfb-/- mice showed that 
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glucose uptake to the cardiac muscle was increased136. These data suggest that inhibition of 
VEGF-B reprograms the endothelium to change substrate utilization – from lipids to 
glucose. 
   
Fig 8. Schematic illustration on the role of VEGF-B in FA-transport 
1: Vegfb expression is coordinated with the expression of mitochondrial proteins to co-regulate lipid uptake 
and β-oxidation. 2: VEGF-B, signals in a paracrine fashion to the receptors VEGFR1 and NRP1 present on 
endothelial cells (ECs), which 3:upregulates the expression of FATPs and induces subsequent transport of 
FAs across the EC layer into tissue cells (4). From 153 
There are some implications linking the VEGF-B signalling pathway to FA-transport and 
diabetes in humans. VEGF-B is upregulated in omental AT from obese subjects compared to 
lean individuals184, suggesting an increased lipid uptake into AT. Also, serum VEGF-B levels 
were positively correlated to total cholesterol and triglyceride (TG) levels in T2D subjects185. 
Furthermore, serum VEGF-B levels were positively associated with polycystic ovary 
syndrome and insulin resistance186. Also, associations between the genes in the VEGF-B 
signalling pathway and traits coupled to lipid handling and diabetes have been detected. 
Vegfr1 sequence variants have been correlated with coronary heart disease187 and body 
weight188. Genetic variants of Nrp1 have been linked with body weight188 and cardiac 
hypertrophy189. A sequence variant in Fatp4 was identified to be associated with the 
metabolic syndrome and insulin resistance190. To conclude, the biological role of VEGF-B 
has for long been enigmatic, with several publications showing diverging, or even opposite 
results. However, both human and mouse data imply that VEGF-B has an important role in 
endothelial FA uptake, via VEGFR1, NRP1, FATP3 and FATP4. 
1.3.3 PGC-1α, master regulator of mitochondrial biogenesis  
Peroxisome proliferator-activated receptor γ coactivator 1α (Ppargc1a / PGC-1α) is a 
transcriptional coactivator that exerts its functions via binding to several transcription factors, 
e.g. estrogen-related receptor alpha (ESRRa)191, peroxisome proliferator-activated receptor 
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gamma (PPARg)192 and nuclear respiratory factor 1 (NRF1)193. PGC-1α is ubiquitously 
expressed in organs such as heart, skeletal muscle, kidney, liver, AT and pancreas194. Several 
different physiological stimuli can induce PGC-1α both transcriptionally and post-
transcriptionally, including exercise, cold and fasting194,195. PGC-1α is synthesised as multiple 
isoforms with somewhat different expression patterns and functions, although the detailed 
function for each isoform is to date not clear196-198.  
Binding of PGC-1α to transcription factors induces specific signalling pathways and the 
biological functions that are regulated by that transcription factor. Importantly, PGC-1α is a 
powerful inducer of mitochondrial biogenesis by co-activating NRF1 and ERRα, and thus 
regulating hundreds of nuclear-encoded genes activating mitochondrial biogenesis and β-
oxidation193. Furthermore, activation of PPARα by PGC-1α increased the expression of 
genes involved in FA import and β-oxidation199,200. PGC-1α also increased lipid anabolism 
in vitro, including intracellular FA and ceramides201. Also in vivo, de novo lipogenesis, fatty 
acid synthase and FATP4 expression were increased in muscle specific PGC-1α transgenic 
mice (muscle creatine kinase PGC-1α transgenic mice, MPGC-1α TG)202,203. Thus, PGC-1α 
can simultaneously coordinate FA import, mitochondrial biogenesis, β-oxidation and de 
novo lipogenesis depending on different extrinsic signals. 
A common pathology in T2D is dysfunctional and insufficient muscular mitochondria204. 
Microarray studies of muscle biopsies from T2D patients showed decreased levels of PGC-
1α as well as genes coding for mitochondrial biogenesis57,205,206. Also, increased muscular 
expression of PGC-1α, increased GLUT4-dependent glucose uptake in vitro207. These data 
suggested that, insulin resistance in T2D might be attributed to reduced levels of or 
dysfunctional PGC-1α and thus decreased mitochondrial content57. Studies using animal 
models have however not been as straightforward. PGC-1α full body knockout (Pgc-1α-/-) 
mice had fewer mitochondria and diminished respiratory capacity, but surprisingly in 
response to HFD the Pgc-1α-/- mice were more insulin sensitive than WT controls208. Mice 
with a specific deletion of PGC-1α in skeletal muscle, did not develop insulin resistance, 
but had an altered glucose homeostasis209. MPGC-1α TG mice displayed reduced insulin 
sensitivity under HFD-feeding despite increased mitochondrial density and activity16,202. In 
rats, long term HFD-feeding increased the expression of Ppargc1a. Also in humans, 3 days 
of overfeeding caused elevated PGC-1α protein levels that returned to basal at the end of 
the study210,211. Moreover, increased PPARα and PGC-1α expression in murine insulin-
resistant and in diabetic hearts have been detected212-214. Therefore, in the absence of 
exercise or during obesity, atypically high PGC-1α levels and thus an increased rate of 
glycogen and fat anabolism may lead to metabolic imbalance, eventually developing into 
diabetes.  
1.3.3.1 Linking PGC-1α to angiogenesis and lipid uptake  
PGC-1α is a major regulator of mitochondrial biogenesis whereas VEGFs are major 
regulators of angiogenesis and lipid uptake. Therefore, it would make sense to couple PGC-
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1α with VEGFs to synchronize cellular and tissue growth via angiogenesis, endothelial 
lipid uptake and mitochondrial biogenesis.  
PGC-1α has in many studies been shown to control VEGF-A expression and consequently 
angiogenesis. Upon starvation, PGC-1α regulated angiogenesis via increased VEGF-A 
expression, mediated via ERRα in myocytes215. Also, exercise and cold induced 
angiogenesis via PGC-1α and VEGF-A in muscle and AT196as well as deletion of PGC-1α 
in cardiomyocytes, lead to vascular defects216. Interestingly, all these angiogenic pathways 
were hypoxia-independent arguing that there might be a difference in how physiological 
and pathological angiogenesis is regulated215,196. In diabetes, vessels and ECs are damaged 
and reduced in number and factors such as AGEs, ROS, and FAs have all been suggested to 
contribute to the diabetic pathology217,218. Upregulation of PGC-1α levels were detected in 
ECs from diabetic patients, and PGC-1α also inhibited endothelial migration via activation 
of Notch signalling. Therefore, hyperglycaemia was thought to activate PGC-1α in ECs that 
in turn would inhibit vessel re-endothelialisation, processes involved, in for example, 
wound healing219.  
As discussed earlier, PGC-1α induced lipid uptake via e.g. CD36 and FATP4. How about 
PGC-1α and lipid uptake in the context of VEGF-B? The expression of VEGF-B was 
closely correlated to the expression of mitochondrial genes controlled by PGC-1α in a 
large-scale survey of the expression of nuclear-encoded mitochondrial genes57. Also, this 
co-expression between VEGF-B and mitochondrial genes was found when analysing 
publically available microarray data136. Vegfb expression clustered together with genes 
coding for oxidative phosphorylation and this co-expression was specific for Vegfb and not 
detected for Vegfa or Plgf136. Furthermore, in an attempt to identify novel PGC-1α targets 
in muscle, array analysis identified Vegfb as a novel myokine in MCK-PGC-1α TG220.  
Thus, these data suggest that by regulating PGC-1α levels, the tissue cell can quickly respond 
to changes in the environment, and as a consequence lipid uptake, mitochondrial biogenesis 
and β-oxidation as well as angiogenesis can be synchronized. 
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2 AIMS OF THIS THESIS 
 
VEGF-B was previously shown to control lipid uptake from the endothelium into tissue cells 
and genetic ablation of Vegfb reduced intra-tissue lipid accumulation in mice. Apart from 
this, little is known regarding the metabolic role of VEGF-B in physiology and 
pathophysiology.  
The aim of this thesis was to characterize the function of VEGF-B in metabolism. 
 
The specific aims include; 
• To optimize a robust protocol for visualization and quantification of 
neutral lipids in different tissues (Paper IV) 
• To identify the upstream regulation of VEGF-B (Paper I) 
• To evaluate if reducing VEGF-B signalling is beneficial for disease 
progression in rodent models of T2D (Paper II) 
• To study whether reducing VEGF-B signalling, is beneficial for the 
disease progression in mouse models of DN (Paper III) 
• To investigate wheather the VEGF-B signalling pathway is present and 
altered in human DN subjects (Paper III) 
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3 PAPERS AND DISCUSSION 
Since the material and methods and the results included in this thesis are discussed and 
presented in detail within each paper, only a short summary of the rationale and the main 
findings are presented and discussed here below.  
3.1 PAPER I; PGC-1 ALPHA COORDINATES MITOCHONDRIAL 
RESPIRATORY CAPACITY AND MUSCULAR FATTY ACID UPTAKE VIA 
REGULATION OF VEGF-B 
The upstream regulatory mechanisms of controlling VEGF-B expression had not previously 
been characterised, and were thus unknown. It had been shown that the expression of VEGF-
B clustered together with the expression of nuclear-encoded mitochondrial genes, and that 
VEGF-B regulated FA-transport136. The co-activator PGC-1α is a major regulator of 
mitochondrial function and energy metabolism221. Increased expressional levels of VEGF-B 
were reported in mice with a specific overexpression of PGC-1α in muscles (MPGC-1α TG 
mice)220. Therefore, we aimed to investigate whether PGC-1α could be a potential direct 
regulator of VEGF-B. 
First, transfection analyses in vitro confirmed that co-expression of ESRRa and PGC-1α 
induced expression of Vegfb luciferase reporter construct containing the first kilobase of the 
5´ untranslated region together with the first exon and the first intron of the Vegfb gene. 
Neither of the other transcription factors tested, NRF1 and PPARg could activate Vegfb. 
Also, we detected a putative ESRRa binding site upstream of the Vegfb gene. Next, we aimed 
to validate these data in vivo, using the MPGC-1α TG mice. Q-PCR analysis of MPGC-1α 
TG muscle revealed that expression of Vegfb was upregulated, and in parallel IMCL 
accumulation was increased, compared to WT littermate. In contrast, when Vegfb was deleted 
in MPGC-1α TG mice, IMCL levels were greatly decreased, however without affecting β-
oxidation. This implies that the reduced IMCL accumulation in MPGC-1α TG/Vegfb-/- mice 
was due to reduced lipid uptake and that PGC-1α can control tissue lipid content via 
regulating VEGF-B expression.  
It has previously been shown that HFD-fed MPGC-1α TG mice developed insulin resistance, 
which was considered paradoxical as mitochondrial biogenesis was increased in these mice16. 
We hypothesized that the insulin resistance in these mice could be due to an upregulation of 
VEGF-B expression and consequently increased IMCL accumulation (Fig 9a). Indeed, 
markedly increased IMCL accumulation was detected in HFD-fed MPGC-1α TG mice. 
Consistently, in HFD-fed MPGC-1α TG/Vegfb-/- mice, IMCL levels were greatly decreased 
and insulin sensitivity restored, and even normalized to lean control levels. These data 
suggested that insulin resistance in MPGC-1α TG mice is due to increased VEGF-B levels 
resulting in enhanced lipid uptake promoting lipotoxicity. 
Taking together, we show both in vitro and in vivo that PGC-1α regulates the expression of 
Vegfb and by this mechanism lipid uptake can be coordinated with mitochondrial biogenesis 
and β-oxidation (Fig 9a). We also provide evidences that the paradoxical phenotype of the 
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MPGC-1α TG HFD-fed mice is due to increased VEGF-B expression and signalling. 
However, whether in humans overfeeding activates the PGC-1α/ESRRa pathway and 
consequently increases Vegfb expression, and if this is the mechanism by which muscular 
lipotoxicity and insulin resistance develops in progressive T2D remains to be established (Fig 
9b). 
  
Fig. 9 Schematic illustration of PGC-1α dependent regulation of VEGF-B and FA uptake. a: During normal 
physiological conditions, PGC-1α coordinates mitochondrial biogenesis and β-oxidation with FA uptake. b: In 
pathological states such as obesity or T2D, VEGF-B and PGC-1α levels could be upregulated, whereas 
mitochondrial function and β-oxidation are known to decline. This would cause a metabolic imbalance where 
FA uptake remains high, whereas the oxidative capacity of the tissue is reduced, resulting in tissue lipid 
accumulation, inducing insulin resistance and T2D (Modified from Mehlem et al under revisionin  Diabetes). 
3.2 PAPER II; TARGETING VEGF-B AS A NOVEL TREATMENT FOR INSULIN 
RESISTANCE AND TYPE 2 DIABETES 
It has previously been shown that inhibition of VEGF-B signalling in unchallenged mice, not 
only reduced FA uptake but also increased glucose uptake into myocytes136. Therefore we 
rationalized that one of the core pathologies causing T2D, namely lipotoxcicity, could be 
targeted by reducing VEGF-B signalling and potentially be beneficial for treating the disease.  
To study this, we first analysed how genetic ablation of Vegfb in two different mouse models 
of obesity and T2D (db/db and HFD-fed mice) affected the development of T2D. In both 
animal models, Vegfb deficient mice showed reduced peripheral lipid deposition and 
improved hyperglycaemia, dyslipidaemia, glucose tolerance as well as enhanced insulin 
sensitivity in comparison to control animals.  
Next, to rule out any possible developmental effects, and to explore the therapeutic potential 
of VEGF-B inhibition we used antibody administration to pharmacologically reduce VEGF-
B signalling in db/db mice. Anti-VEGF-B antibody treatment reduced peripheral lipid 
accumulation, enhanced glucose tolerance and improved dyslipidaemia compared to control 
treated db/db mice. Interestingly, also pancreatic islet architecture and β-cell function were 
maintained by anti-VEGF-B treatment in db/db mice. Whether this improved effect on the β-
cells is due to reduced metabolic pressure from lipotoxicity, glucotoxicity, both, or other 
unknown factors remain to be investigated.  
Since db/db mice have been selected to spontaneously develop T2D, we sought to analyse the 
effects of anti-VEGF-B antibody treatment on T2D in another diabetic model and in a 
different species. To address this, HFD-fed rats were treated with an anti-VEGF-B antibody 
or isotype-matched control antibody, and subjected to a hyperinsulinemic-euglycaemic clamp 
assay, where insulin sensitivity is monitored. Inhibition of VEGF-B signalling increased 
Normal state Pathological state
β-oxidation
VEGF-B
  Insulin 
resistance
β-oxidationPGC-1α PGC-1α
VEGF-B
Mitochondria Fatty acids
a) b)
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insulin sensitivity and glucose uptake to skeletal muscle and heart compared to control 
antibody injected rats.  
Recently, diverging results from our study have been found when comparing the two 
available different Vegfb-/- strains side by side on HFD, including the one used in paper II178. 
Dijkstra et al could not detect any differences between WT and Vegfb-/- mice in glucose 
tolerance or dyslipidaemia after HFD-feeding. However, Dijkstra et al analysed plasma lipids 
after 18h of fasting, whereas we analysed postprandial levels. Importantly, Dijkstra et al 
reported that the Bellomo mice were on a partly mixed background222, inconsistent with our 
results. To further analyse the effects of reducing VEGF-B signalling during HFD conditions, 
would therefore be of importance. 
Taken together, in the diabetic experimental animal models studied here, peripheral lipid 
accumulation mediated by VEGF-B is a major part of the diabetic pathology (Fig. 10 a-b). 
Importantly, we show using both genetic and pharmaceutical tools that VEGF-B signalling 
can be targeted, to reduce IMCL accumulation and to increase glucose uptake into peripheral 
tissues (Fig. 10c). However, whether VEGF-B signalling pathway can be used to treat T2D 
also in patients remains to be established. 
 
Fig. 10 Schematic illustration of the role of Vegfb in physiological and pathophysiological states. 
a) In the insulin sensitive state, Vegfb is secreted and binds to 1) endothelial VEGFR1 and NRP1 2). FATP3 and 
FATP4 are upregulated and subsequently FAs are transported across the endothelium and through the 3) tissue 
cell and transported to the 4) mitochondria for β-oxidation. a) Insulin and glucose are transported through the 
endothelium, insulin signalling is activated and glucose is taken up by the cell. b) In the insulin resistant, 
diabetic state, the expression of Vegfb is upregulated 1) and consequently endothelial FATP expression is 
increased 2), more FA are fed to the tissue cell 3) which leads to an 4). increased ectopic lipid accumulation. a). 
Ectopic lipid accumulation inhibits insulin signalling and thus glucose uptake. c) By inhibiting Vegfb via anti-
VEGF-B treatment 1) Vegfb signalling is reduced 2) and less FAs are transported across the endothelium 3). 
Thus, ectopic lipid accumulation is reduced 4) and the tissue cell is a). re-sensitized to insulin and glucose is 
taken up  
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3.3 PAPER III; REDUCING VEGF-B SIGNALLING AMELIORATES RENAL 
LIPOTOXICITY AND PROTECTS AGAINST DIABETIC NEPHROPATHY   
In db/db mice with genetic ablation of Vegfb, reduced levels of glucosuria, were detected in 
comparison to control mice (paper II). Therefore, we aimed to investigate whether 
lipotoxicity is a cause of not only diabetes, but also of DN, and if inhibition of VEGF-B 
signalling can improve the outcome of DN.   
Firstly, the kidney phenotype of a standard mouse model of DN, db/db was examined with 
regards to VEGF-B signalling. In db/db mice, the progression of diabetes was associated with 
increased expression levels of Vegfb in whole kidney lysates, together with an increase in 
glomerular lipid accumulation and podocyte loss. Therefore, we hypothesized that inhibition 
of VEGF-B signalling, and thus less glomerular lipid accumulation might be beneficial in 
DN. To explore this, we first analysed how genetic deficiency of Vegfb affected the 
development of DN in two different mouse models, db/db and HFD-feeding. Reduced 
glomerular lipotoxicity, improved renal function as well as diminished GBM thickening, 
GME and podocyte loss were detected upon Vegfb deletion in both animal models.  
Next, the therapeutic potential of reducing VEGF-B signalling was studied using antibody 
administration to db/db BKS and HFD-fed mice. Importantly, improved effect on insulin 
resistance and dyslipidaemia was confirmed in anti-VEGF-B antibody treated HFD- fed 
mice, thus questioning the findings of Dijkstra et al. However, in contrast to Paper II only 
modest effects on blood glucose levels were detected upon VEGF-B inhibition in db/db BKS 
mice. Two different mouse backgrounds were used in these studies. Paper II used a db/db 
BKS/ C57/Bl6 mix whereas here we used a pure db/db BKS mouse line. It has been shown 
that the db/db mice on a BKS background develop a more severe hyperglycaemia that 
progress much faster than on a C57/BL6 background223, which we also could confirm (Paper 
III). Therefore, anti-VEGF-B antibody treatment seems to be efficient at targeting 
hyperglycaemia only if the diabetic pressure is intermediate (Paper II), and cannot halt 
hyperglycaemia when the progression is very aggressive (Paper III). Nevertheless, several 
hallmarks of DN could be improved with anti-VEGF-B antibody treatment, even despite that 
hyperglycaemia was not greatly altered. Reduced glomerular lipotoxicity, improved renal 
function as well as diminished GBM thickening, GME and podocyte loss were detected upon 
anti-VEGF-B antibody treatment. Hence, hyperglycaemia does not contribute significantly to 
the pathogenesis of DN, in this setting, 
Renal dysfunction is not only a comorbidity of T2D, but also frequently found in T1D 
subjects. Lipotoxicity is being contributed to an increasingly larger role also in the pathology 
of T1D. Therefore, we next sought to investigate whether anti-VEGF-B antibody treatment 
could be beneficial in STZ-injected mice, a mouse model for T1D. Animals injected with 
STZ in combination with control antibody treatment, displayed severe renal dysfunction and 
glomerular lipotoxicity causing podocyte loss, traits that were near to normalized with anti-
VEGF-B antibody administration.  
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To fully understand the therapeutic potential of reducing VEGF-B signalling, we next 
investigated whether VEGF-B expression was altered in human DN. Microarray analysis of 
renal biopsies from patients with DN revealed that glomerular VEGF-B production is 
increased compared to healthy subjects. This suggests that VEGF-B signalling is present and 
activated in human DN and that lipotoxicity could presumably be targeted using anti-VEGF-
B antibody treatments.  
Next, as glomerular VEGF-B expression levels were increased in human DN subjects, we 
aimed to explore the consequences of increased VEGF-B signalling specifically in the 
podocytes. Interestingly, in mice with podocyte-specific overexpression of VEGF-B, 
microalbuminuria could be induced in unchallenged mice, however with age the level of 
leakage was not aggravated. Upon HFD-feeding, a steady rise in albuminuria that developed 
into macroalbuminuria was detected in mice with podocyte-specific overexpression of 
VEGF-B. Hence, both elevated VEGF-B levels, as well as dyslipidaemia achieved by HFD-
feeding, are needed for the progression of albuminuria to occur in these mice.  
Our data in paper III suggest that glomerular-derived VEGF-B will promote ectopic lipid 
accumulation. During persisted elevated circulating FA levels, as in diabetes, podocyte 
VEGF-B expression is increased, causing lipotoxicity and podocyte insulin resistance with 
subsequent podocyte loss and impaired glomerular structure and function (Fig 11). Therefore, 
renal lipotoxicity is an important element of DN, and reducing VEGF-B signalling can 
ameliorate renal lipotoxcicity. This represents a novel approach to treat DN (Fig 11). 
 
Fig 11, Schematic illustration of VEGF-B signaling in podocytes in healthy subjects and DN  
In the healthy, insulin sensitive state, the circulating levels of FAs are low, as well as podocyte expression of 
Vegfb. Consequently FA uptake is low and insulin sensitivity maintained. In DN, plasma levels of FAs are 
increased, podocyte expression of Vegfb is upregulated and thus the uptake of lipids from the circulation into the 
podocyte is enhanced, causing lipotoxicity, insulin resistance and proteinuria (Modified from Falkevall et al. in 
submission). 
3.4 PAPER IV; IMAGING OF NEUTRAL LIPIDS BY OIL RED O FOR 
ANALYZING THE METABOLIC STATUS IN HEALTH AND DISEASE 
All of the papers presented previously in this thesis required a method that enabled the 
detection of lipids within tissue cells. Not many easy and reliable techniques existed that 
could enable both quantification and visualization of intra tissue lipids.  
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Therefore, we aimed to develop a protocol that enabled the detection of neutral lipids as well 
as LD morphology, using Oil red-O (ORO). By using ORO, the lipid content could readily be 
quantified. To validate the robustness of the protocol, three different mouse models were 
analysed for lipid accumulation in three different tissues. Both in liver, heart and muscle, the 
highest lipid accumulation was detected in db/db animals, followed by HFD-fed and lastly 
normal diet. Hence, a protocol enabling easy quantification of neutral lipids and distribution 
is presented, that can be performed using only basic laboratory and computer equipment.  
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4 FUTURE PERSPECTIVES 
The results included in this thesis are exciting for a broad scientific audience. We show that 
lipotoxcicity is an important contributor to the progression of T2D (paper II) and DN (paper 
III), and that it can be targeted. This opens up for several interesting future implications. 
Could the development of other comorbidities associated with diabetes be halted using anti-
VEGF-B agents as well, such as diabetic foot ulcers, stroke, hepatic steatosis and 
cardiovascular disease? Dyslipidaemia is a known risk factor for all of these comorbidities, 
however little research on the subject particularly in regards to intra-tissue lipid accumulation 
are available.  
Furthermore, the identification of PGC-1α as a regulator of VEGF-B in paper I prompts 
several interesting questions. Mainly, may inappropriately high PGC-1α upregulate VEGF-B 
expression levels also in a human diabetic patients and if so, does increased VEGF-B 
signalling drive IMCL accumulation? Also, what are the underlying factors behind atypically 
high PGC-1α levels in obesity and T2D? 
Several questions of a more specific character also rise with the studies presented in this 
thesis. Among others, is reduced podocyte loss by inhibiting VEGF-B signalling due to a 
relief of lipotoxicicity-mediated insulin resistance? Interestingly, pioglitazone, an agonist for 
PPARs, was effective in reducing albumin excretion and podocyte injury in early-stage 
diabetic nephropathy224. Pioglitazone functions as an insulin sensitizer and decreases lipid 
content in peripheral tissues225,226. Even though pioglitazone has been implicated with several 
side effects227,228, this study shows that podocyte survival can be targeted using a drug that 
decreases lipid accumulation, in line with our findings in paper III.  
Finally, an important question that rises from our studies is whether hyperglycaemia is the 
pathology to target for diabetes and diabetic complications. VEGF-B acts by lowering intra-
tissue lipid levels and in paper III we can almost halt the progression of DN in several mouse 
models, without reducing glucose levels. This is in line with large patient cohort studies 
where modest or no effect was found on the outcome of diabetic complications after 
intensively controlling and lowering blood glucose levels. High glucose levels are obviously 
toxic for the cell and can interfere with, among others, the insulin signalling pathway. 
However, if hyperglycaemia were the main pathological driver behind diabetic 
complications, a larger effect after intensively controlling it, would have been expected. Thus, 
the large cohort data as well as our studies suggest, that diabetic complications are not 
primarily caused by increased glucose levels, instead focus of research and drug development 
could be shifted towards lipotoxcicty. 
Your theory is crazy, but it's not crazy enough to be true. Niels Bohr 
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